We report that mice immunized with a phosphate immunogen produced polyclonal catalytic antibodies (PCAbs) that catalysed the hydrolysis of carbaryl, a widely used broad-spectrum carbamate insecticide that exerts toxic effects in animals and humans. The reaction catalysed by the PCAbs (IgGs) obeyed MichaelisMenten kinetics in itro with the following values at pH 8.0 and 25 mC: K m $ 8.0 µM, k cat l 4.8i10 −$ -5.8i10 −" , k cat \ k non-cat l 5.6i10"-6.8i10$ (where k non-cat is the rate constant of the reaction in the absence of added catalyst). The PCAbs were also active in whole sera under physiological conditions in itro. The PCAbs induced in i o were also active in i o, as
INTRODUCTION
Since the first demonstration of antibody catalysis in 1986, investigators have prepared antibodies that catalyse almost all kinds of known chemical reactions [1] [2] [3] [4] . Because catalytic antibodies have high efficiency and specificity, there has been interest in their application for medical treatment. Catalytic antibodies have been prepared that catalyse the hydrolysis of anti-cancer prodrugs in itro and therefore have the potential to diminish the non-specific toxicity associated with many commonly used chemotherapeutic agents [5] [6] [7] . A highly active monoclonal catalytic antibody, 15A10, was prepared that hydrolysed cocaine to non-toxic, non-addictive products. Passive immunization with this artificial enzyme blunted the reinforcing effect of cocaine in rats, suggesting that this approach may have therapeutic value [8, 9] . Although encouraging, this response was achieved using mouse monoclonal catalytic antibodies, which typically induce deleterious anti-antibody responses in humans, thus limiting their clinical application.
A novel approach for generating therapeutic antibodies is to induce the formation of polyclonal catalytic antibodies (PCAbs) by active immunization in i o. This approach avoids the problematic immune responses associated with monoclonal catalytic antibodies. Several studies have demonstrated that PCAbs active in itro can be generated relatively simply, rapidly and cheaply [10] [11] [12] [13] [14] . Here, we provide the first evidence that enzymically active PCAbs can be useful as therapeutic reagents in i o. To achieve this, we immunized mice with an antigen that was designed according to the structural features of carbaryl (Sevin, 1-naphthyl N-methylcarbamate) and its hydrolytic transition state. Our rationale was that the elicited antibodies would catalyse carbaryl hydrolysis by stabilizing the hydrolytic transition state of carbaryl via structural and charge complementarity in the antibody-binding pocket.
Abbreviations used : EDAC, 1-ethyl-3-(3-dimethylaminopropyl)carbodi-imide ; PCAb, polyclonal catalytic antibody ; PNAb, polyclonal non-catalytic antibody ; k non-cat , rate constant in the absence of added catalyst. 1 To whom correspondence should be addressed (e-mail mwilkins!mail.mdanderson.org).
immunization with the phosphate immunogen decreased the mouse blood concentration of carbaryl. To our knowledge, this is the first report demonstrating that active immunization generates antibodies possessing therapeutic catalytic function in i o. We propose that active immunization schemes that induce enzymically active antibodies may provide a highly specific therapeutic approach for degrading toxic substances.
Key words : carbaryl, hydrolysis, immunized mice, polyclonal antibody.
Carbamate poisoning is a well-known toxicological problem causing morbidity and mortality in both developing and industrialized countries [15] . Carbaryl is a major carbamate insecticide marketed throughout the world ; it has been used since 1958 for both outdoor agricultural and indoor house-pet-related insect control [16] . Its acute toxic effects on the central and peripheral nervous systems are due to inhibition of acetylcholinesterase at nerve endings, which causes accumulation of acetylcholine and consequent overstimulation of nicotinic receptors [17] . In addition, recent studies show that chronic exposure to carbaryl may induce neurotoxicity, teratogenesis, tumour initiation, miscarriage and preterm delivery in humans and animals [18] [19] [20] [21] [22] . We reasoned that the generation of PCAbs that can catalyse the hydrolysis of carbaryl in i o would degrade carbaryl and reduce its toxic effects.
In the present investigation, a phosphate analogue of the hydrolytic transition state of carbaryl was conjugated with BSA as the immunogen and injected into mice to produce therapeutic PCAbs in their sera, which in turn catalysed the hydrolysis of carbaryl both in itro and in i o. We propose that active immunization schemes that induce enzymically active antibodies may provide a highly specific therapeutic approach for degrading toxic substances.
EXPERIMENTAL Materials
1-Ethyl-3-(3-dimethylaminopropyl)carbodi-imide (EDAC), Nhydroxysuccinimide, sodium oxybate, Tween 20 and chicken egg albumin were obtained from Sigma, St. Louis, MO, U.S.A. ; Freund's adjuvant, complete and incomplete, were obtained from Life Technologies, Grand island, NY, U.S.A. ; BSA was
Scheme 1 Synthetic routes to generate (a) hapten (product IV), phosphate immunogens (products V and VI) and (b) amide immunogen (product VIII)
CEA, chicken egg albumin ; DMAP, 4-dimethylaminopyridine.
provided by Roche Molecular Biochemicals, Mannheim, Germany ; Protein A-Sepharose CL 4B was from Amersham Pharmacia Biotech, Uppsala, Sweden. All other chemicals were of analytical grade.
Synthesis of phosphate immunogens V and VI (Scheme 1a)
Preparation of γ-hydroxyethyl butyrate (product I)
Ethyl iodide (16 ml, 0.197 mol) was added to a stirred solution of γ-hydroxy sodium butyrate (16.39 g, 0.13 mol) in N,N-dimethylformamide (260 ml), and the mixture was stirred at room temperature for 12 h. The mixture was extracted with ethyl acetate (2i250 ml). The extracts were washed with water three times and then evaporated under reduced pressure (3388 Pa) to remove the solvents. Later, after the temperature rose to 102-106 mC, a fraction was obtained that on redistillation (104-106 mC\3388 Pa) produced a clear colourless liquid (product I Preparation of α-naphthyl γh-(ethyl butyrate) hydrogen phosphate (product III)
Product II was prepared according to the literature [23] . The prepared product was a clear colourless syrup, boiling point 197-201 mC\2711 Pa (reference value [23] , 199-201 mC and 2711 Pa). Product II (1340 mg, 5.14 mmol) was added to a stirred solution of product I (220 mg, 1.66 mmol) in a 2 : 1 (v\v) mixture of pyridine and acetonitrile (4.8 ml) at 0 mC. This was stirred at 0 mC for 1 h, distilled water (4 ml) was added and the reaction mixture was stirred for another 3 h at room temperature. Solvents were removed in acuo, and the residue was dissolved in 0.5 M NaHCO $ (50 ml) and extracted with diethyl ether (2i50 ml). The aqueous solution was acidified with HCl ( pH 1-2) and extracted with ethyl acetate (3i50 ml). The combined ethyl acetate extracts were evaporated in acuo to remove ethyl acetate and give a crude product. The crude product was purified by column chromatography on silica H (gradient elution with chloroform\ethanol, from 10 : 1 to 3 : 1, v\v) to give product III as a pale-yellow solid (280 mg, 50 %). "H-NMR (90 MHz ; C#HCl
Preparation of α-naphthyl γh-butyrate hydrogen phosphate (product IV)
Distilled water (1.8 ml) and 1 M NaOH (400 µl) were added to a stirred solution of product III in tetrahydrofuran (2.5 ml). After 5 min, a second aliquot of 1 M NaOH (400 µl) was added. The reaction mixture was stirred at room temperature for 1 h, then acidified with HCl to pH 1.0, and finally extracted with ethyl acetate (3i20 ml). The combined ethyl acetate extracts were dried and concentrated in acuo to give the crude product.
Recrystallization from ethyl acetate gave pure product IV (40 mg, 65 %). "H-NMR (90 MHz ; C#HCl 
Preparation of the immunogens V and VI
EDAC (100 mg, 0.52 mmol) was added dropwise over 5 h to a stirred solution of product IV (40 mg, 0.15 mmol), N-hydroxysuccinimide (100 mg, 0.78 mmol) and BSA (60 mg) in redistilled water (4 ml) and pyridine (100 µl). The reaction mixture was further stirred at room temperature for 16 h and then dialysed against running tap water for 3 days. The dialysis residue was freeze-dried to give immunogen V as a pale-yellow powder (56 mg). Immunogen VI (50 mg) was synthesized in the same manner as immunogen V except that chicken egg albumin was used instead of BSA.
Preparation of the amide immunogen VIII (Scheme 1b)
Preparation of N-(1-naphthyl) 4h-hydroxycarbonyl butamide (product VII) 1-Aminonaphthalene (31 mg, 0.22 mmol) was coupled with glutaric anhydride (38 mg, 0.33 mmol) in dichloromethane (10 ml) using 4-dimethylaminopyridine (30 mg, 0.24 mmol) as a base. The reaction was monitored by TLC. The crude product was dissolved in 0.05 M NaOH (10 ml), and the suspension was removed by filtration. The filtrate was acidified with HCl to pH 1.0, and the resulting suspension was precipitated by centrifugation to yield a pellet. Recrystallization of the pellet from ethyl acetate gave the pure product VII (30 mg, 52 %). "H-NMR
Preparation of immunogen VIII
Immunogen VIII (40 mg) was synthesized in the same manner as immunogen V except that product VII, a non-toxic analogue of carbaryl, was used instead of product IV.
Production of antisera
Female Balb\c mice, weighing 20-25 g, were each immunized with an emulsion of 0.1 mg of immunogen V dissolved in water (0.2 ml) mixed with Freund's complete adjuvant (0.2 ml). The immunization was repeated after 10 days using Freund's incomplete rather than complete adjuvant. Thereafter, the mice were immunized twice more with 0.05 mg of immunogen V in 0.4 ml of water at 10-day intervals. A control group of nonimmunized mice were treated in the same way using saline only. The mice were bled on the 35th day of the immunization schedule. The blood was incubated at 37 mC for 2 h, allowed to clot overnight at 4 mC, and then centrifuged. The serum was extracted and stored at k20 mC. The antiserum dilution curves were measured by ELISA, using immunogen VI as the antigen to coat the wells. Immunogen VI has the same hapten as immunogen V but has a different carrier protein to reduce non-specific binding.
Purification of IgG from antisera
The antiserum ($ 0.6 ml) from four mice (M-61, M-62, M-63 and M-64) was precipitated separately by (NH % ) # SO % according to the method of Thomason and Hebert [24] , dialysed and then concentrated using 60 % poly(ethylene glycol). The resulting solution (2 ml) was subjected to chromatography on a Protein A-Sepharose CL 4B fast-flow column (5 ml), and the eluate was monitored at 280 nm using a spectrophotometer (model ES-1 ; Bio-Rad). The absorbed IgG was eluted with 0.1 M citrate buffer ( pH 3.5), and 0.5 ml fractions of the eluate were collected in tubes containing 1 M Tris\HCl buffer ( pH 9.0, 0.05 ml\tube). The combined fractions for each mouse containing IgG (2 µM, $ 2 ml) were subjected to dialysis with distilled water for 3 days, and the dialysis residue was freeze-dried to produce PCAbs (PCAb-61, PCAb-62, PCAb-63 and PCAb-64, respectively) in the form of an off-white powder. Control polyclonal non-catalytic antibody (PNAb) preparations from (PNAb-61, PNAb-62, PNAb-63 and PNAb-64) were prepared from four nonimmunized mice using the same method. The concentration of IgG was determined by absorbance at 280 nm assuming a specific absorption coefficient (A" % " cm ) of 14 [11] , and the purity was demonstrated by SDS\PAGE. The concentration of IgG in whole blood was determined based on the assumption that the serum represents 50 % of the blood volume and that 90 % of the IgG was recovered after purification.
Kinetics of carbaryl hydrolysis
The rate of carbaryl hydrolysis was calculated by measuring the increase in the product α-naphthol with time. The concentration of α-naphthol was calculated from the absorbance of carbaryl and α-naphthol in 30 mM Tris\HCl buffer ( pH 8.0) containing 0.4 % (v\v) ethanol at 25 mC. We chose to measure α-naphthol absorbance at 270 nm, as this wavelength afforded the best distinction between α-naphthol and carbaryl. The concentration of α-naphthol in the reaction mixture was calculated from the equation :
where C is the concentration of α-naphthol in the reaction mixture, L is the distance to the light source (1 cm), [S] ! is the initial concentration of carbaryl, and ε " (9.08i10$ M −" :cm −" ) and ε # (2.66i10$ M −" :cm −" ) are the molar absorption coefficients of carbaryl and α-naphthol at 270 nm respectively. The substrate was prepared in ethanol to a volume of 8 µl and was then mixed with 992 µl of water to a final concentration of 0-24 µM. In some cases, the reaction mixtures contained 0.2 µM PCAb or 0.2 µM PNAb. Figure 1 [10] . To determine the antibody-catalysed reaction rate of immunized sera (as compared with non-immunized sera) with the background reaction in sera, 64 µl of serum was added to a 1 ml reaction mixture containing 10 µM carbaryl. The reaction was carried out at pH 7.4 and 38 mC, with 7.7 mM K + , 152 mM Na + , 2.5 mM Ca# + and 4.1 mM Mg# + , which is similar to physiological conditions in the mouse [25] . The in itro inhibition experiments involving hapten IV, a transition-state analogue, were carried out by adding different concentrations of hapten IV to a 1 ml reaction mixture containing 0.2 µM PCAb (IgGs) and 10 µM carbaryl at pH 8.0 and 25 mC.
Determination of carbaryl hydrolysis by catalytic antibody in vivo
Two groups of Balb\c mice (10 mice for each group), weighing 20-25 g each, were immunized with either immunogen V or VIII for 5 weeks (as described above) before carbaryl administration. A control group of 10 mice that were not immunized were housed in parallel. The mice were given water but no food for 16 h prior to carbaryl administration. Each mouse was given carbaryl intragastrically at a dose of 9.7 mg\kg of body weight. The mice were bled completely 1 h after carbaryl administration. The concentration of carbaryl in the blood was determined by an assay involving the coupling of p-nitrobenzenediazonium fluoroborate with α-naphthol, a product of the alkaline hydrolysis of carbaryl [26] . To avoid the contamination of free α-naphthol, 0.1 ml of 3 % KMnO % was incubated with the blood for 2 min, extracted with chloroform three times and dried in acuo. The concentration of free α-naphthol in the blood was expected to be very low since it is known to be efficiently transformed into α-naphthyl glucoside, α-naphthyl sulphate or another water-soluble substance, all of which are separated from carbaryl by chloroform extraction [27] .
RESULTS

Antibody production
A previous study identified a monoclonal antibody capable of hydrolysing the p-nitrophenyl N-aryl carbamate through the B Ac 2 pathway [28] . This was regarded as a major advance in the catalytic antibody field, as previous studies had indicated that carbamate ester hydrolysis occurs predominantly via an E "c B mechanism instead [29] . Here, we investigated whether the related carbamate, carbaryl, could also be hydrolysed through the highly disfavoured B Ac 2 pathway by PCAbs (Scheme 2). With this goal in mind, we used a stable tetrahedral-phosphate analogue of the hydrolytic transition state of carbaryl generated through the B Ac 2 pathway as the hapten determinant to produce PCAbs (Scheme 1, product IV). This hapten IV was conjugated to BSA (Scheme 1, immunogen V) and injected multiple times into four mice. The average antiserum titre was 1\36 000 5 days after the last immunization, as determined by ELISA. The average concentration of IgG in the whole blood was 3.6 µM. The PCAbs (IgG) from the antisera were isolated by (NH % ) # SO % precipitation and chromatography on Protein A-Sepharose. Control PNAb (IgG) preparations from non-immunized mice were prepared using the same procedure.
Catalytic specificity
We tested whether the purified PCAb preparations were capable of hydrolysing carbaryl in itro. Figure 1 shows the initial rates of carbaryl hydrolysis by PCAb-61 compared with the negative control PNAb-61 preparation. The data show that PCAb-61 produced a greater rate of carbaryl hydrolysis than PNAb-61. The similar first-order rate constants for PNAb-61 (k PNAb l 9.10i10 −& s −" ) and Tris\HCl buffer alone (k non-cat l 8.59i 10 −& s −" ; where k non-cat is the rate constant in the absence of added catalyst) indicated that the IgG from non-immunized mice had no catalytic activity or contaminating esterases. Because PCAbs and PNAbs were prepared using the same procedure, we reasoned that PCAb preparations did not have contaminating esterases. Further evidence for specificity was the finding that the catalytic activity of PCAbs was inhibited by 80 % when co-incubated with the transition-state analogue hapten IV in itro (at a hapten IV\IgG ratio of 0.075 ; results not shown). We conclude that catalytic antibodies inhibitable by a specific hapten were responsible for specifically catalysing the hydrolysis of carbaryl.
Scheme 2 The proposed mechanism for antibody-catalysed hydrolysis of carbaryl through the B Ac 2 pathway
Kinetic characteristics of PCAb
The initial rates of hydrolysis of carbaryl in the presence of 0.2 µM PCAb were determined as a function of substrate concentration, represented by a plot of corrected versus [S] . We found that the IgG fractions from the four immunized mice (PCAb-61-64) catalysed the hydrolysis of carbaryl with typical Michaelis-Menten kinetics ( Figure 2 and Table 1 ). Because there are two active sites in each antibody molecule, the concentration of catalytic sites in the PCAb would be twice the total IgG concentration. Meanwhile, due to the fact that only a small fraction of the total IgG sample was anti-hapten IgG, the concentration of PCAb in the IgG preparation would be much less than the total concentration of the IgG sample. Depending on the estimate of the efficient PCAb concentration, which could vary between 1 and 100 % of the total IgG concentration [10] , the values for the rate constant k cat and the ratio k cat \k non-cat were in the ranges 4.8i10 −$ -5.8i10 −" s −" and 5.6i10"-6.8i10$ (Table  1) . This demonstrates that despite the existence of structural heterogeneity in the PCAbs, the catalytic properties of the active species of antibodies were similar and that the differences among them were not readily detectable as deviations from the singlesite saturation mode.
Catalytic activity of whole sera under physiological conditions
To determine whether the catalytic antibodies were active in whole sera (rather than as purified IgGs) under physiological conditions, the reaction was carried out at pH 7.4 and 38 mC, under ionic conditions similar to those found in mouse sera (see the Experimental section). We found that sera from immunogen V-immunized mice catalysed the reaction twice as quickly as sera from non-immunized mice, indicating that the induced antibodies indeed had catalytic activity under physiological conditions ( Figure 3) . In contrast, when we used immunogen VIII (a conjugate of a non-toxic analogue of carbaryl and BSA ; Scheme 1) to immunize the mice, the sera from these control mice catalysed the reaction at a rate similar to that of the sera from non-immunized mice (results not shown). This indicates that immunogen VIII-immunized mice did not generate antibodies catalysing the hydrolysis of carbaryl.
Figure 2 Demonstration of adherence to the Michaelis-Menten equation of the hydrolysis of carbaryl catalysed by PCAb-61
Each data point represents the meanpS.D. for three independent measurements.
Catalytic antibodies decrease the concentration of carbaryl in vivo
It was reported previously that the majority of carbaryl administered through the stomach accumulates in the blood and thus is an available target for hydrolysis by serum PCAbs [30] . If serum PCAbs catalyse the hydrolysis of carbaryl in i o, we reasoned that the concentrations of carbaryl in the blood should be decreased in immunogen V-immunized mice. To test this, 10 immunogen V-immunized mice (which had an average antiserum titre of 1\35 500 and a catalytic activity similar to that shown in Figure 3 ) and 10 non-immunized mice were each administered 9.7 mg\kg carbaryl. After 1 h, the mice were bled completely, and the concentration of carbaryl in the blood was measured. We found that the average concentration of carbaryl in the immunized mice was 245.4 µM, which was 121 µM lower than the average value in non-immunized mice. To test whether the decrease in carbaryl serum concentration in the immunized mice was due simply to antibody binding rather than catalysis, we immunized 10 mice with a non-toxic analogue of carbaryl (immunogen VIII) that does not induce catalytic antibodies, but which does induce antibodies that bind to carbaryl (average antiserum titre, 1\30 000), and administered carbaryl to them by the same method. The resulting average concentration of carbaryl was 359.4 µM, which was similar to the concentration of carbaryl in non-immunized mice. Collectively these results suggest that the decrease in carbaryl concentration in mice immunized with immunogen V was due to catalysis and not to antibody binding.
DISCUSSION
Our study is the first to demonstrate that an active immunization procedure can be used to generate catalytic antibodies active in i o. We found that a synthetic immunogen possessing the structural features of a carbaryl hydrolytic transition state induced the generation of PCAbs that were catalytically active and protected mice against a challenge with the insecticide carbaryl.
We provided several lines of evidence that suggest that immunization in i o decreased the level of carbaryl mainly as a result of carbaryl hydrolysis catalysed by the induced antibodies. First, we demonstrated that the antibodies induced in i o possessed specific catalytic activity. Purified IgG from the immunized mice catalysed the hydrolysis of carbaryl with typical Michaelis-Menten kinetics (Table 1 and Figure 2 ). The rate of catalysis was much greater for sera from immunized mice than that for sera from non-immunized mice under physiological conditions (Figure 3) . We showed that this catalytic activity was derived from the polyclonal antibodies induced by immunogen V and not from non-specific IgGs or an adventitious enzyme impurity (Figure 1) . The specificity of catalytic activity was demonstrated by the observation that specific hapten inhibited the catalytic activity of the in i o-induced antibodies. Secondly, immunogen V-immunized mice had lower serum carbaryl levels than non-immunized mice 1 h after carbaryl administration. In contrast, mice immunized with a non-toxic analogue of carbaryl (immunogen VIII) did not exhibit a decrease in serum carbaryl levels.
Although difficult to determine directly in i o, the kinetics of catalytic antibodies can be estimated by using in itro kinetic parameters. Our results showed that 1 h after administration of 9.7 mg\kg carbaryl, the carbaryl concentration in the blood of the immunogen V-immunized mice was 245.4 µM, which far exceeds the K m values (7-8 µM) of the catalytic antibodies (Table  1) . Therefore, we estimated that the hydrolytic velocity of the catalytic antibodies was close to their maximum velocity [V max l (1.9-2.3)i10 −* M:s −" ; Table 1 ]. Because the total IgG concentration in the blood averaged 3.6 µM, the concentration of the substrate carbaryl in the blood exceeded that of the catalytic antibodies (1-10 % of total IgG [14] ). Consequently, the hydrolytic velocity should be related directly to the concentration of the catalytic antibodies, and thus the catalytic velocity in the blood was likely to be close to the value of $ 3.8i10 −) M:s −" (3.6\0.2iV max ; Table 1 ). According to this estimate, the catalytic antibodies were capable of decreasing the carbaryl concentration by 135 µM in 1 h. This value is in close agreement with the difference between the concentrations of carbaryl in the blood of the immunogen V-immunized and non-immunized mice (121 µM) and thus provides further support for the notion that catalytic antibodies catalysed the degradation of carbaryl in i o. However, it should be noted that endogenous enzymes may also participate in the degradation of carbaryl. The existence of such enzymes would explain why we detected hydrolytic activity in non-immunized mice (Figure 3 ). The role of exogenous enzymes in carbaryl degradation may be limited, as carbaryl is known to inhibit the activity of most esterases [31] . Regardless of the presence of endogenous catalytic activities, our study clearly shows that immunization in i o increases the catalytic activity in serum as a result of induced antibodies.
It should be emphasized that our estimate for enzyme kinetics in i o was based on reaction conditions in itro, which are different from those in i o. Moreover, we performed our in itro reaction in 30 mM Tris\HCl buffer ( pH 8.0) at 25 mC, whereas mouse blood has a pH of $ 7.4 and a temperature of 38 mC. There are many metal ions in the blood, including K + , Na + , Ca# + and Mg# + , which were not present in our in itro reactions [25] . However, we found that k cat \k non-cat was not significantly affected by a change of pH from 7.1 to 8.5 (results not shown). Also, we found that k cat \k non-cat was only increased 1.4-fold at 40 mC compared with the ratio at 25 mC (results not shown). Thus, for the particular catalytic antibodies studied here, the kinetic values determined in itro were a good predictor of PCAb activity in i o. We propose that the active immunization approach for generating catalytic antibodies described herein can be used to protect against many target substrates, including pesticides, other toxic agents and narcotic drugs. Furthermore, this strategy can be used for treatment of enzyme deficiencies and cardiovascular diseases. Although the catalytic activity of PCAbs generated in past studies was modest [10, 13] , improvements in hapten design methods and immunization strategies may lead to an increase in the catalytic activity of antibodies and broaden the application of catalytic antibodies for therapeutic strategies in i o.
